Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy.
Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy.
复制标题
继发于静脉依替膦酸治疗后的骨扫描中骨骼不可视化。
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
J. Eary
中科院分区：
文献类型：
--
作者：
S. Hommeyer;D. M. Varney;J. Eary
依地膦酸二钠（EHDP）治疗通常用于治疗与恶性肿瘤相关的高钙血症，分期骨扫描是评估广泛转移性疾病患者的一部分。在高剂量EHDP治疗的患者中，骨扫描剂的摄取明显减少。该病例说明了这一发现：一名乳腺癌患者在骨扫描分期前接受了两次500毫克静脉注射剂量的EHDP。99mTc-MDP注射后3小时未见骨骼显像。观察大转移部位的血池活性和摄取。
Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease. In these patients in whom high dose EHDP therapy has been instituted, uptake of the bone scan agent is markedly diminished. The case presented illustrates this finding: a breast cancer patient who had received two 500-mg intravenous doses of EHDP prior to bone scan staging. No skeletal visualization was present at 3 hr after 99mTc-MDP injection. Blood-pool activity and uptake in large metastatic sites were observed.